Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Amgen Inc (AMGN)

Amgen Inc (AMGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 148,047,344
  • Shares Outstanding, K 537,533
  • Annual Sales, $ 28,190 M
  • Annual Income, $ 6,717 M
  • EBIT $ 6,218 M
  • EBITDA $ 10,289 M
  • 60-Month Beta 0.56
  • Price/Sales 4.57
  • Price/Cash Flow 10.54
  • Price/Book 19.84

Options Overview Details

View History
  • Implied Volatility 26.77% ( +0.30%)
  • Historical Volatility 17.81%
  • IV Percentile 62%
  • IV Rank 22.90%
  • IV High 55.92% on 11/20/24
  • IV Low 18.11% on 05/21/24
  • Put/Call Vol Ratio 0.26
  • Today's Volume 14,850
  • Volume Avg (30-Day) 13,472
  • Put/Call OI Ratio 0.67
  • Today's Open Interest 133,704
  • Open Int (30-Day) 168,824

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 30 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 5.01
  • Number of Estimates 12
  • High Estimate 5.31
  • Low Estimate 4.71
  • Prior Year 4.71
  • Growth Rate Est. (year over year) +6.37%

Price Performance

See More
Period Period Low Period High Performance
1-Month
257.05 +7.15%
on 01/06/25
278.00 -0.93%
on 01/23/25
+10.93 (+4.13%)
since 12/24/24
3-Month
253.30 +8.73%
on 12/19/24
328.25 -16.09%
on 11/08/24
-40.27 (-12.76%)
since 10/24/24
52-Week
253.30 +8.73%
on 12/19/24
346.85 -20.59%
on 07/25/24
-30.08 (-9.85%)
since 01/24/24

Most Recent Stories

More News
These Were the 5 Worst-Performing Stocks in the Dow Jones Industrial Average in 2024

The Dow Jones Industrial Average (DJIA) is a group of 30 U.S. industry leaders. It's often looked at as a proxy for the market, since its components' performance is indicative of what's happening in the...

JNJ : 146.82 (+0.12%)
MRK : 95.55 (-1.12%)
NKE : 73.57 (-0.97%)
AMGN : 275.42 (-0.89%)
BA : 176.06 (-1.37%)
SNY's Sarclisa Gets EU Nod for Expanded Use in Multiple Myeloma

Sanofi SNY announced that the European Commission (“EC”) has granted marketing authorization to expand the use of its multiple myeloma (MM) drug, Sarclisa (isatuximab).With this nod, Sarclisa is now...

JNJ : 146.82 (+0.12%)
AMGN : 275.42 (-0.89%)
SNY : 52.48 (+0.96%)
BMY : 59.67 (+0.90%)
J&J's Q4 Earnings Beat, Stock Down on Tepid 2025 Sales Guidance

Johnson & Johnson’s JNJ fourth-quarter 2024 earnings came in at $2.04 per share, which beat the Zacks Consensus Estimate of $2.00. Earnings declined 10.9% from the year-ago period. Adjusted earnings...

ITCI : 127.35 (+0.22%)
JNJ : 146.82 (+0.12%)
KVUE : 20.78 (+0.14%)
AMGN : 275.42 (-0.89%)
Can the 8 Worst-Performing Dow Jones Stocks in 2024 Beat the S&P 500 in 2025?

2024 was an excellent year for the major stock market indexes. But the Dow Jones Industrial Average (DJINDICES: ^DJI) had just a 12.9% return, compared to 23.3% for the S&P 500 (SNPINDEX: ^GSPC) and 28.6%...

CVX : 155.65 (-0.23%)
$SPX : 6,101.24 (-0.29%)
MRK : 95.55 (-1.12%)
JNJ : 146.82 (+0.12%)
NKE : 73.57 (-0.97%)
AMGN : 275.42 (-0.89%)
UNH : 532.51 (+0.52%)
MCD : 285.46 (+0.36%)
COMP : 6.99 (+1.16%)
$DOWI : 44,424.25 (-0.32%)
BA : 176.06 (-1.37%)
Should You Buy, Sell or Hold J&J Stock Ahead of Q4 Earnings?

Key TakeawaysThe Zacks Consensus Estimate for JNJ Q4 sales and earnings is $22.5 billion and $2.01 per share, respectively.JNJ's performance has impressed, as the company exceeded earnings expectations...

ITCI : 127.35 (+0.22%)
JNJ : 146.82 (+0.12%)
KVUE : 20.78 (+0.14%)
AMGN : 275.42 (-0.89%)
2 Magnificent Stocks to Buy That Are Near Their 52-Week Lows

Some investors believe you make money when you buy a stock, not when you sell it. The logic behind this idea is that investing in the right stock at the right time -- and holding onto it for a while --...

CRSP : 43.42 (-1.83%)
AMGN : 275.42 (-0.89%)
Got $5,000? These 3 Growth Stocks Are Trading Near Their 52-Week Lows.

A $5,000 investment can go a long way, especially if you're loading up on fairly cheap stocks that may possess a lot of upside in the long run. By investing $5,000, you can ensure that if you pick a great...

NVDA : 142.62 (-3.12%)
NVO : 87.97 (+8.47%)
AMD : 122.84 (-0.16%)
LLY : 785.41 (+2.45%)
PLD : 118.93 (+0.33%)
AMGN : 275.42 (-0.89%)
Regeneron Stock Plunges 35.6% in Six Months: Fold or Hold?

Shares of Regeneron Pharmaceuticals, Inc. REGN have dropped 35.6% in the past six months compared with the industry’s decline of 12.3%.The stock has underperformed the sector and the S&P 500 Index during...

BAYRY : 5.4901 (-0.90%)
REGN : 675.79 (-2.71%)
RHHBY : 38.0500 (-0.05%)
AMGN : 275.42 (-0.89%)
SNY : 52.48 (+0.96%)
3 High-Yield Dividend Stocks to Buy in 2025

High-yield dividend stocks may not appeal to some investors. However, if you're among those investors looking for income, stocks that pay dividends regularly can be great additions to your portfolio.

ABBV : 170.30 (-0.22%)
AMGN : 275.42 (-0.89%)
PFE : 26.09 (+0.31%)
Amgen’s Q4 2024 Earnings: What to Expect

Drug manufacturing giant Amgen is expected to announce its fourth-quarter results in the upcoming month and analysts expect single-digit growth in earnings.

XLV : 144.31 (+0.16%)
$SPX : 6,101.24 (-0.29%)
AMGN : 275.42 (-0.89%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Amgen Inc. is the leading biotech companies world wide, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health & nephrology and neuroscience markets. It developed two most successful drugs, Epogen & Neupogen. Amgen successfully launched two...

See More

Key Turning Points

3rd Resistance Point 281.22
2nd Resistance Point 279.29
1st Resistance Point 277.36
Last Price 275.42
1st Support Level 273.49
2nd Support Level 271.57
3rd Support Level 269.63

See More

52-Week High 346.85
Fibonacci 61.8% 311.11
Fibonacci 50% 300.08
Fibonacci 38.2% 289.04
Last Price 275.42
52-Week Low 253.30

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar